Acquisition of TeneoTwo for its clinical-stage T-cell engager completed
AstraZeneca has completed the acquisition of TeneoTwo, Inc . (TeneoTwo)[i], including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.[1] AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. Financial considerations AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m. Under the